Hosted on MSN4mon
GSK's Respiratory Drug Nucala Meets Goal in COPD Study
GSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic obstructive pulmonary disease (COPD), met its primary endpoint.
Hosted on MSN1mon
FDA to review GSK’s Nucala for COPD
The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala (mepolizumab) as an add-on maintenance treatment for chronic obstructive pulmonary ...
pharmaphorum8y
GSK’s severe asthma drug Nucala recommended by NICE
These are triggered by the IL-5 molecule, which Nucala blocks and helps reduce the number of eosinophils in the airways. NICE have set out restrictive guidelines for the drug’s use. It is ...
pharmaphorum1d
GSK says Nucala hits the target in new COPD trial
GSK has been studying Nucala in COPD for some time, and in 2017 reported mixed results for the drug in two earlier phase 3 trials called METREX and METREO. METREX involved patients with a range of ...